Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Fiche publication
Date publication
juillet 2020
Journal
Gynecologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FAVIER Laure, Dr KAMINSKY Marie-Christine, Dr GANTZER Justine
Tous les auteurs :
Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, Pautier P, Angeles MA, Delanoy N, Lefeuvre-Plesse C, Cancel M, Treilleux I, Augereau P, Lavoue V, Kalbacher E, Berton Rigaud D, Selle F, Nadeau C, Gantzer J, Joly F, Guillemet C, Pomel C, Favier L, Abdeddaim C, Venat-Bouvet L, Provansal M, Fabbro M, Kaminsky MC, Lortholary A, Lecuru F, Coquard IR, de La Motte Rouge T
Lien Pubmed
Résumé
Malignant ovarian germ cell tumors are rare tumors, affecting young women with a generally favorable prognosis. The French reference network for Rare Malignant Gynecological Tumors (TMRG) aims to improve their management. The purpose of this study is to report clinicopathological features and long-term outcomes, to explore prognostic parameters and to help in considering adjuvant strategy for stage I patients.
Mots clés
Prognostic factors, Rare malignant ovarian tumors, Stage I, TMRG
Référence
Gynecol. Oncol.. 2020 Jul 2;: